Anne S. Tsao
Leiden University · 616 works · 46,526 citations · h-index 83
Top works
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
- Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
- Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer
- Malignant Pleural Mesothelioma
- Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
- Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
- Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- Pathogenic Germline Variants in 10,389 Adult Cancers
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma